Atrion Corporation’s Short Interest Sees Major Increase
December 21, 2022
Trending News ☀️
Atrion Corporation Intrinsic Stock Value – Atrion Corporation ($NASDAQ:ATRI) is a publicly traded company listed on the New York Stock Exchange. It’s a leading provider of medical technology and services to healthcare professionals and patients around the world. The company offers an array of products and services that help healthcare providers, institutions, and governments to enhance patient care, reduce costs, and improve clinical outcomes. Recently, Atrion Corporation’s short interest saw a major increase. Short interest is the total number of shares investors have sold short and not yet covered. When the short interest increases, it typically means that investors have a negative outlook on the stock. The increase in short interest is an indication that investors are bearish on the company’s prospects.
The company’s stock price has been volatile over the past few months, and it may have been affected by the rise in short interest. Investors should be cautious when considering investing in the stock. They should carefully analyze the company’s financials, its competitive position in the market, and other factors before making any decisions. Short selling can be a risky strategy, and investors should understand the risks associated with it before making any trades. It’s important to also note that short interest can change rapidly, so investors need to stay informed about the company’s latest developments. In summary, Atrion Corporation’s short interest has seen a major increase recently, which may be an indication that investors have a negative outlook on the stock. Investors should carefully consider their options before investing in the stock and understand the risks associated with short selling.
Stock Price
This trend has been mainly driven by news coverage of the company which has been largely positive. On Monday, ATRION CORPORATION‘s stock opened at $557.7 and closed at $551.1, representing a 0.5% decrease from the previous closing price of 553.6. This is likely due to investors taking profits in the wake of the news-driven rally. Analysts believe that the increase in short interest could be due to the company’s recent financial performance. ATRION CORPORATION has reported solid earnings growth and its stock price has been steadily increasing over the last few months.
Furthermore, the company’s balance sheet remains strong with no debt and a healthy cash position. This has likely attracted investor interest. Overall, the recent increase in short interest could be seen as a positive sign for ATRION CORPORATION’s stock. With news coverage remaining largely positive and the company’s financial performance continuing to remain strong, investors may see this as an opportunity to take advantage of the current market conditions and capitalize on potential gains from ATRION CORPORATION’s stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atrion Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 180.94 | 34.81 | 18.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atrion Corporation. More…
| Operations | Investing | Financing |
| 38.92 | -6.05 | -29.4 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atrion Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 271.95 | 25.68 | 138.36 |
Key Ratios Snapshot
Some of the financial key ratios for Atrion Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.2% | -1.7% | 21.4% |
| FCF Margin | ROE | ROA |
| 5.2% | 9.8% | 8.9% |
VI Analysis – Atrion Corporation Intrinsic Stock Value
ATRION CORPORATION is a great opportunity to invest in for the long-term, and its fundamentals can be easily analyzed using VI app. After taking into consideration various factors such as the company’s financials, industry, and competitive landscape, VI Line’s fair value for ATRION CORPORATION share is estimated at $755.7. Currently, the stock is trading at $551.1, meaning it is undervalued by 27%. This presents investors with an excellent opportunity to buy the stock at a discounted price. Furthermore, given the company’s strong fundamentals, there is potential for capital appreciation over the long-term. Thus, ATRION CORPORATION is a great choice for those looking to invest in a stable and well-established business. More…
VI Peers
In the medical device industry, Atrion Corp competes against LeMaitre Vascular Inc, AtriCure Inc, and Nova Eye Medical Ltd. All four companies offer products that are used to treat cardiovascular diseases. Atrion has a history of innovation, which has allowed it to become a leader in the industry. The company’s competitors have also been successful in their own right, and each offers a unique product portfolio.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease. Its products are used by vascular surgeons and interventionalists for arterial and venous vessel reconstruction. The company’s products include stents, balloons, and other devices. It has operations in the United States, Europe, Canada, Australia, and Asia.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. is a leading manufacturer of medical devices that provide surgical ablation solutions for the treatment of atrial fibrillation and other cardiac conditions. The company has a market cap of 2.14B as of 2022 and a Return on Equity of -7.05%. AtriCure’s products are sold in over 50 countries and are backed by a strong clinical evidence base. The company’s mission is to improve the lives of patients by providing minimally invasive solutions that treat cardiac conditions with fewer complications and shorter hospital stays.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company that provides ophthalmic products and services. As of 2022, the company had a market capitalization of 40.84 million and a return on equity of -18.79%. Nova Eye Medical Ltd offers a variety of ophthalmic products and services, including cataract surgery, refractive surgery, ocular implants, and more. The company has a presence in both the United States and Canada.
Summary
Investing in Atrion Corporation can be a great opportunity for investors looking for a potential long-term return. The company has recently seen a major increase in its short interest, indicating that there is a lot of investor interest in the company. This could provide the potential for significant capital gains if Atrion is able to deliver on its promises. Atrion Corporation is a medical technology company that specializes in providing products and services to the health care industry. The company’s products range from medical devices, such as oxygen delivery systems, to laboratory and diagnostic systems. The company also provides services like installation and maintenance of its products. Atrion has a presence in the United States, Europe, Asia, and South America. The company is well-positioned to benefit from recent advances in healthcare technology, such as artificial intelligence and robotics.
This should help it to continue to grow its revenue and profits in the future. The company’s stock is currently trading at a relatively low price relative to its peers, which could be a great entry point for investors looking for a potential long-term return. Atrion’s stock is also highly liquid, which can provide added security when investing in the company. Overall, Atrion Corporation is an interesting opportunity for investors looking for potential long-term returns. The company has seen a major increase in short interest recently, indicating strong investor interest. Atrion’s impressive track record of growth and its position to benefit from advances in healthcare technology could provide investors with the potential for significant capital gains in the future.
